AstraZeneca’s dividend hike divides opinion
[ad_1] Patent worries persist Shareholder discontent at AGM When AstraZeneca (AZN) announced a dividend hike ahead of a potentially fractious AGM last week, it was bound to be viewed as a sweetener for investors who’ve gone sour on the stock. Although its shares have now recovered after lurching downward in the wake of the group’s…